Lutetium
The rarest REE, lutetium trades in mere tens of tonnes yet tops the price charts. Lu-doped LYSO scintillators are essential for high-resolution PET/CT scanners, while Lu-177-based radiopharma is one of the fastest-growing targeted cancer treatments. Production is an unavoidable by-product of heavy-REE separation from Chinese ion-adsorption clays. Any disruption or quota change drives extreme price volatility and incents medical-isotope recyclers.
Supply Dynamics
-
Heavy-REE separation in China supplies >90 % of Lu oxide; Myanmar feed is minor.
-
Annual production only 30–40 t, so single mine outages move price materially.
-
Recycling from spent medical isotopes remains experimental but promising.
-
Western stockpiling for radiopharma smooths hospital isotope pricing.
-
New HREE projects (Australia, USA) may add grams-per-t levels, unlikely to flood market.
Demand Dynamics
-
PET/CT installations expand 6-8 % CAGR worldwide, lifting LYSO crystal demand.
-
Lu-177 radiotherapies grow >20 % CAGR, constrained more by isotope capacity than lutetium supply.
-
Alkylation catalysts and high-index glass use modest, price-inelastic volumes.
-
Defence and research lasers provide niche, strategic demand.
-
No large-scale substitutes meet density and decay requirements simultaneously.